Esbriet (Perfenidone), a potential TGF-β inhibitor and Ofev (Nintedanib), a tyrosine kinase inhibitor are the only two USFDA approved drugs available to treat PF till date (Ley et al., 2011). The gene discussed is TGFB1; the disease is pemphigus foliaceus.